Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of non-anaplastic stage III and 'inoperable' Wilms tumour treated in the UKW3 trial.
Irtan S, Messahel B, Moroz V, Taylor RE, Grundy R, Kelsey A, Vujanic G, Pritchard-Jones K; Renal Tumours Committee of the Children's Cancer and Leukaemia Group (CCLG). Irtan S, et al. Among authors: moroz v. Radiother Oncol. 2019 Feb;131:1-7. doi: 10.1016/j.radonc.2018.10.026. Epub 2018 Dec 15. Radiother Oncol. 2019. PMID: 30773174 Clinical Trial.
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol.
Anderton J, Moroz V, Marec-Bérard P, Gaspar N, Laurence V, Martín-Broto J, Sastre A, Gelderblom H, Owens C, Kaiser S, Fernández-Pinto M, Fenwick N, Evans A, Strauss S, Whelan J, Wheatley K, Brennan B. Anderton J, et al. Among authors: moroz v. Trials. 2020 Jan 17;21(1):96. doi: 10.1186/s13063-019-4026-8. Trials. 2020. PMID: 31952545 Free PMC article.
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Brennan B, Kirton L, Marec-Bérard P, Gaspar N, Laurence V, Martín-Broto J, Sastre A, Gelderblom H, Owens C, Fenwick N, Strauss S, Moroz V, Whelan J, Wheatley K. Brennan B, et al. Among authors: moroz v. Lancet. 2022 Oct 29;400(10362):1513-1521. doi: 10.1016/S0140-6736(22)01790-1. Lancet. 2022. PMID: 36522207 Clinical Trial.
High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial.
Hutchison CA, Cockwell P, Moroz V, Bradwell AR, Fifer L, Gillmore JD, Jesky MD, Storr M, Wessels J, Winearls CG, Weisel K, Heyne N, Cook M. Hutchison CA, et al. Among authors: moroz v. Lancet Haematol. 2019 Apr;6(4):e217-e228. doi: 10.1016/S2352-3026(19)30014-6. Epub 2019 Mar 11. Lancet Haematol. 2019. PMID: 30872075 Clinical Trial.
250 results